Canada markets closed

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4200-0.0200 (-4.55%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.4400
Open0.4400
BidN/A x N/A
AskN/A x N/A
Day's Range0.4200 - 0.5200
52 Week Range0.0010 - 2.4500
Volume10,718
Avg. Volume19,640
Market Cap5.082M
Beta (5Y Monthly)3.58
PE Ratio (TTM)N/A
EPS (TTM)-4.6810
Earnings DateNov 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est140.00
  • CNW Group

    MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

    Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") dated August 26, 2022, the Compa

  • GlobeNewswire

    Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

    DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for the nine months ended September 30, 2022. Company Highlights In 2022, Mydecine continued to define its focus and clinical trial execution strategy. The Company reached several milestones with the goal to

  • CNW Group

    MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO

    Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing o